TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy.

Oden-Gangloff, A; Di Fiore, F; Bibeau, F; Lamy, A; Bougeard, G; Charbonnier, F; Blanchard, F; Tougeron, D; Ychou, M; Boissière, F; Le Pessot, F; Sabourin, J-C; Tuech, J-J; Michel, P; Frebourg, T

Oden-Gangloff, A; Di Fiore, F; Bibeau, F; Lamy, A; Bougeard, G; Charbonnier, F; Blanchard, F; Tougeron, D; Ychou, M; Boissière, F; Le Pessot, F; Sabourin, J-C; Tuech, J-J; Michel, P; Frebourg, T.

Affiliation

Oden-Gangloff A; Inserm U614, Faculty of Medicine, Institute for Biomedical Research, University of Rouen, Rouen, France.

Br J Cancer ; 100(8): 1330-5, 2009 Apr 21.

Article in En | MEDLINE | ID: mdl-19367287

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Colorectal Neoplasms/drug therapy; Colorectal Neoplasms/genetics; Mutation; Tumor Suppressor Protein p53/genetics; Aged; Amino Acid Substitution; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms/pathology; DNA, Neoplasm/genetics; DNA, Neoplasm/isolation & purification; Disease Progression; Dose-Response Relationship, Drug; Exons; Female; Genotype; Humans; Male; Middle Aged; Neoplasm Metastasis; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins/genetics; Proto-Oncogene Proteins p21(ras); ras Proteins/genetics

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Colorectal Neoplasms / Tumor Suppressor Protein p53 / Antibodies, Monoclonal / Mutation / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2009 Document type: Article

Fulltext

XML

PubMed Links

Search on Google